149 research outputs found

    Ventricular function, myocardial delayed enhancement and patient-reported quality of life in adolescents and adults with repaired tetralogy of Fallot

    Get PDF
    INTRODUCTION: In patients with repaired tetralogy of Fallot (TOF), right ventricular myocardial delayed enhancement (MDE) and diastolic dysfunction are common, and have been associated with decreased exercise capacity and increased arrhythmia. Predictors of quality of life (QOL) have not been reported in this population. PURPOSE: We assessed the hypothesis that a greater degree of MDE in adolescents and adults with repaired TOF would correlate with diastolic dysfunction and decreased QOL

    Ventricular function, myocardial delayed enhancement and patient-reported quality of life in adolescents and adults with repaired tetralogy of Fallot

    Get PDF
    INTRODUCTION: In patients with repaired tetralogy of Fallot (TOF), right ventricular myocardial delayed enhancement (MDE) and diastolic dysfunction are common, and have been associated with decreased exercise capacity and increased arrhythmia. Predictors of quality of life (QOL) have not been reported in this population. PURPOSE: We assessed the hypothesis that a greater degree of MDE in adolescents and adults with repaired TOF would correlate with diastolic dysfunction and decreased QOL

    Development of quality metrics for ambulatory pediatric cardiology: Chest pain

    Full text link
    ObjectiveAs part of the American College of Cardiology Adult Congenital and Pediatric Cardiology Section effort to develop quality metrics (QMs) for ambulatory pediatric practice, the chest pain subcommittee aimed to develop QMs for evaluation of chest pain.DesignA group of 8 pediatric cardiologists formulated candidate QMs in the areas of history, physical examination, and testing. Consensus candidate QMs were submitted to an expert panel for scoring by the RAND‐UCLA modified Delphi process. Recommended QMs were then available for open comments from all members.PatientsThese QMs are intended for use in patients 5–18 years old, referred for initial evaluation of chest pain in an ambulatory pediatric cardiology clinic, with no known history of pediatric or congenital heart disease.ResultsA total of 10 candidate QMs were submitted; 2 were rejected by the expert panel, and 5 were removed after the open comment period. The 3 approved QMs included: (1) documentation of family history of cardiomyopathy, early coronary artery disease or sudden death, (2) performance of electrocardiogram in all patients, and (3) performance of an echocardiogram to evaluate coronary arteries in patients with exertional chest pain.ConclusionsDespite practice variation and limited prospective data, 3 QMs were approved, with measurable data points which may be extracted from the medical record. However, further prospective studies are necessary to define practice guidelines and to develop appropriate use criteria in this population.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/140026/1/chd12509.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/140026/2/chd12509_am.pd

    MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors

    Get PDF
    BACKGROUND MicroRNA (miRNA) expression profiles have been described in pancreatic ductal adenocarcinoma (PDAC), but these have not been compared with pre-malignant pancreatic tumors. We wished to compare the miRNA expression signatures in pancreatic benign cystic tumors (BCT) of low and high malignant potential with PDAC, in order to identify miRNAs deregulated during PDAC development. The mechanistic consequences of miRNA dysregulation were further evaluated. METHODS Tissue samples were obtained at a tertiary pancreatic unit from individuals with BCT and PDAC. MiRNA profiling was performed using a custom microarray and results were validated using RT-qPCR prior to evaluation of miRNA targets. RESULTS Widespread miRNA down-regulation was observed in PDAC compared to low malignant potential BCT. We show that amongst those miRNAs down-regulated, miR-16, miR-126 and let-7d regulate known PDAC oncogenes (targeting BCL2, CRK and KRAS respectively). Notably, miR-126 also directly targets the KRAS transcript at a "seedless" binding site within its 3'UTR. In clinical specimens, miR-126 was strongly down-regulated in PDAC tissues, with an associated elevation in KRAS and CRK proteins. Furthermore, miR-21, a known oncogenic miRNA in pancreatic and other cancers, was not elevated in PDAC compared to serous microcystic adenoma (SMCA), but in both groups it was up-regulated compared to normal pancreas, implicating early up-regulation during malignant change. CONCLUSIONS Expression profiling revealed 21 miRNAs down-regulated in PDAC compared to SMCA, the most benign lesion that rarely progresses to invasive carcinoma. It appears that miR-21 up-regulation is an early event in the transformation from normal pancreatic tissue. MiRNA expression has the potential to distinguish PDAC from normal pancreas and BCT. Mechanistically the down-regulation of miR-16, miR-126 and let-7d promotes PDAC transformation by post-transcriptional up-regulation of crucial PDAC oncogenes. We show that miR-126 is able to directly target KRAS; re-expression has the potential as a therapeutic strategy against PDAC and other KRAS-driven cancers

    Attaching DNA to Nanoceria: Regulating Oxidase Activity and Fluorescence Quenching

    Get PDF
    This document is the Accepted Manuscript version of a Published Work that appeared in final form in Applied Materials and Interfaces copyright © American Chemical Society after peer review and technical editing by publisher. To access the final edited and published work see Pautler, R., Kelly, E. Y., Huang, P.-J. J., Cao, J., Liu, B., & Liu, J. (2013). Attaching DNA to Nanoceria: Regulating Oxidase Activity and Fluorescence Quenching. ACS Applied Materials & Interfaces, 5(15), 6820–6825. https://doi.org/10.1021/am4018863Cerium oxide nanoparticles (nanoceria) have recently emerged as a nanozyme with oxidase activity. In this work, we present a few important interfacial properties of nanoceria. First, the surface charge of nanoceria can be controlled not only by adjusting pH but also by adsorption of simple inorganic anions. Adsorption of phosphate and citrate gives negatively charged surface over a broad pH range. Second, nanoceria adsorbs DNA via the DNA phosphate backbone in a sequence-independent manner; DNA adsorption inhibits its oxidase activity. Other anionic polymers display much weaker inhibition effects. Adsorption of simple inorganic phosphate does not have the inhibition effect. Third, nanoceria is a quencher for many fluorophores. These discoveries provide an important understanding for further use of nanoceria in biosensor development, materials science, and nanotechnology.University of Waterloo || Canadian Foundation for Innovation || Natural Sciences and Engineering Research Council || Ontario Ministry of Research and Innovation |
    corecore